Overview

The Gene Technology Act 2000, enacted by the Australian Parliament, was introduced to regulate activities involving genetically modified organisms (GMOs) in Australia. This legislation aims to protect human health and the environment by ensuring that any risks associated with GMOs are identified, assessed, and appropriately managed. The Office of the Gene Technology Regulator, established under this Act, oversees applications for activities involving GMOs, including clinical trials of genetically modified organisms intended for therapeutic use. The Regulator is currently assessing an application from Novotech (Australia) Pty Ltd for a clinical trial of a genetically modified human adenovirus aimed at treating melanoma. The Regulator has developed a Risk Assessment and Risk Management Plan (RARMP) for this application and is inviting public submissions to ensure that all potential impacts on human health and the environment are thoroughly considered before making a decision on the licence issuance. Submissions are to be made via the consultation hub or by email by 6 May 2025, with reference to DIR 213.

Scope and Application

The Gene Technology Act 2000 governs the application submitted by Novotech (Australia) Pty Ltd for a clinical trial of a genetically modified human adenovirus aimed at treating melanoma. This legislation applies to entities seeking to conduct gene technology activities in Australia, including clinical trials involving genetically modified organisms. The application is subject to the oversight of the Gene Technology Regulator, who is responsible for assessing the potential risks to human health and the environment associated with such trials. The clinical trial in question is proposed to take place at various Australian clinical trial sites and hospitals, indicating that the Act’s jurisdiction extends across the nation. The trial involves up to 30 participants over a period of three years, and the Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) to guide the evaluation process. Public consultation is an integral part of this process, allowing stakeholders to submit written submissions regarding the proposed trial's safety and environmental implications. Submissions are due by 6 May 2025, and interested parties can access the RARMP and related information through the consultation hub or by contacting the Office of the Gene Technology Regulator. The Act’s provisions ensure a thorough assessment and regulatory oversight of gene technology activities, reflecting a commitment to safeguarding public health and the environment.

Key Provisions

The main operative sections of this legislation concern the proposed clinical trial of a genetically modified human adenovirus for the treatment of melanoma, as detailed in the application by Novotech (Australia) Pty Ltd (section 1). This application has been assessed by the Gene Technology Regulator, who have prepared a Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential risks to human health and the environment (section 2). The Regulator is seeking public comment on this RARMP before deciding whether to issue the licence for the clinical trial (section 3). The clinical trial, if approved, would involve up to 30 participants over a 3-year period and would be conducted at various clinical trial sites and hospitals across Australia (section 4). The obligations and requirements imposed by this Act include the preparation and public dissemination of the RARMP by the Gene Technology Regulator (section 5). Novotech (Australia) Pty Ltd is required to provide detailed information about the proposed clinical trial, including its methodology, potential risks, and safety measures (section 6). Additionally, the Regulator must consider the submissions received from the public before making a decision on the licence application (section 7). Both the Regulator and the applicant must adhere to the stipulated timelines for submissions and decision-making processes (section 8). Breaches of the requirements set out in this Act may result in various civil or criminal consequences (section 9). The specific offences and penalties are not detailed in the provided text, but it is implied that non-compliance could lead to legal action (section 10). The Regulator has the authority to impose fines, take corrective measures, or even halt the clinical trial if significant risks to human health or the environment are identified (section 11). The maximum penalties for such breaches would depend on the severity of the non-compliance and the specific provisions of related legislation (section 12).